In vivo experiments have shown that knocking down SHMT2 can considerably decrease the expansion of GC tumors, suggesting a therapeutic effect focused on the inhibition of SHMT2 and HIF1α, which in turn can prevent the activation of the STAT3 pathway [63]. Here, HIF1A is linked to gastric cancer.